CJC-1295 vs Somatropin
CJC-1295 is a growth hormone-releasing hormone receptor agonist built on the N-terminal 29-amino-acid fragment of human GHRH, existing as a DAC-conjugated form that binds albumin and a non-DAC form more accurately called modified GRF(1-29). Somatropin is recombinant 191-amino-acid human growth hormone, an approved therapeutic since the mid-1980s with one of the larger clinical evidence bases in endocrinology. The pairing is framed as secretagogue versus exogenous hormone: one asks the pituitary to release growth hormone, the other supplies it. No published study has given both to the same subjects or run them as parallel arms, so the comparison is entirely indirect. It is also lopsided in a way that no amount of careful reading fixes, because one side rests on a handful of small phase I and phase II studies from 2005 to 2009 and the other on decades of randomised trials, registries and consensus statements.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No trial or experiment has been published in which CJC-1295 and somatropin were administered to the same subjects, whether as parallel arms, crossover or combination. Searches of PubMed and Europe PMC returned only anti-doping analytical methods in which both appear as target analytes, and scoping reviews of image and performance enhancing drugs that discuss the two in separate sections. Neither category generates comparative pharmacodynamic data. The closest published analogue is not a study of CJC-1295 at all: Neyzi and colleagues randomised 43 prepubertal children with growth hormone deficiency of hypothalamic origin to low-dose GHRH(1-29)-NH2, high-dose GHRH(1-29)-NH2 or growth hormone for six months, and reported that height velocity was comparable between the high-dose releasing-hormone group and the growth hormone group while an increase in height standard deviation score for bone age occurred only in the growth hormone arm. That study used the unmodified parent fragment rather than either CJC-1295 form, in children with a specific hypothalamic deficiency, so it illustrates the shape of the question rather than answering it for these two compounds.
Side by side.
| CJC-1295 | Somatropin | |
|---|---|---|
| Evidence maturity | Early clinical | Approved drug |
| Studies cited here | 16 | 16 |
| Published 2023 or later | 8 | 13 |
| Newest paper | 2026 | 2026 |
| Molecular class | A synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone. The DAC form carries a maleimidopropionyl linker forming a covalent complex with circulating albumin; the non-DAC form retains only backbone modifications resisting dipeptidyl peptidase-IV cleavage. | Recombinant human growth hormone itself, a 191-amino-acid protein identical to the pituitary hormone, acting directly at the growth hormone receptor through the JAK/STAT pathway and largely via hepatic and local IGF-1 induction. |
| Where the effect is produced | Upstream, at the GHRH receptor on the anterior pituitary. The response therefore depends on somatotroph reserve, and hypothalamic somatostatin rhythm continues to shape output; a frequent-sampling study reported that GH secretion remained pulsatile during continuous stimulation, with pulse frequency and amplitude essentially unchanged. | Downstream, bypassing the pituitary entirely. Effect does not depend on somatotroph reserve, which is why it works in classical growth hormone deficiency where a releasing-hormone analogue would have nothing to act on. |
| Regulatory status | No marketing authorisation in any jurisdiction, for either form. It appears on the World Anti-Doping Agency Prohibited List, and most literature published since 2019 concerns doping-control detection rather than clinical use. | Approved since the mid-1980s across childhood and adult growth hormone deficiency, Turner syndrome, Prader-Willi syndrome, small-for-gestational-age short stature and idiopathic short stature, with international consensus statements governing its use. |
| Size and nature of the human evidence | A small number of phase I and phase II studies conducted between 2005 and 2009, all with the DAC-conjugated form. No peer-reviewed randomised controlled trial of the non-DAC modified GRF(1-29) form was identified, although that is the form combination material usually describes. | Network meta-analyses spanning thousands of participants, including an 18-trial network of 3137 patients and a 16-trial synthesis of 2435 paediatric patients, alongside a prospective registry of 5040 children covering 19,878 patient-years. |
| Endpoints measured | Endocrine surrogates only: growth hormone concentration, IGF-1 concentration, pulsatility and serum protein profile changes. Single injections raised mean GH roughly 2- to 10-fold for six or more days and IGF-I roughly 1.5- to 3-fold for nine to eleven days. No clinical outcome endpoint has been tested. | Clinical outcomes: height velocity, adult height attainment, body composition, and long-term surveillance of mortality and malignancy. First-year height velocity response differed by diagnosis, exceeding idiopathic short stature by about 0.80 cm per year in complete growth hormone deficiency. |
| Long-term safety surveillance | None exists. Long-term safety, effects on body composition, lean mass, sleep or recovery, and glucose tolerance during sustained IGF-1 elevation remain unestablished for both forms. | Extensive but not unqualified. A Korean registry reported adverse drug reactions in 7.0% of participants and a malignancy standardised incidence ratio of 1.1, and a consensus statement concluded the reviewed evidence did not support an association with tumour recurrence in cancer survivors, while a meta-analysis of mortality in adults concluded that selection and time bias precluded high-quality evidence that replacement improves mortality. |
| Where the contemporary literature is heading | Toward detection. Recent publications are LC-MS/MS and nano-LC methods for GHRH analogues in urine and equine plasma, plus narrative reviews of unapproved peptide self-administration. | Toward long-acting weekly analogues. Somapacitan, somatrogon, lonapegsomatropin and pegylated formulations are benchmarked against daily somatropin, with broadly comparable growth outcomes and an unexplained first-year BMI rise reported with the long-acting schedule. |
And what it does not.
The mechanistic contrast is genuine and is the reason the pairing exists, but no published experiment has ever tested it by giving both compounds to the same subjects. What each literature separately supports is not of the same order. Somatropin has decades of randomised trials, network meta-analyses, international consensus statements and registry surveillance covering clinical endpoints such as adult height, body composition, malignancy incidence and mortality, together with honest acknowledgement of where that evidence is weak, including contested diagnostic thresholds and the limits of observational mortality data. CJC-1295 has a handful of phase I and phase II studies from 2005 to 2009, all conducted with the DAC-conjugated form, all measuring endocrine surrogates rather than any clinical outcome, and none addressing the non-DAC modified GRF(1-29) form that most combination material describes. The one published randomised comparison of a releasing-hormone analogue against growth hormone used the unmodified GHRH(1-29) fragment in 43 children with hypothalamic growth hormone deficiency, and even there height velocity was comparable while height standard deviation score for bone age improved only in the growth hormone arm. That is not evidence about CJC-1295. Neither the relative efficacy nor the relative safety of these two compounds has been measured, and one of them holds no marketing authorisation anywhere and appears on the Prohibited List.
Common questions.
- Has CJC-1295 ever been tested against recombinant growth hormone in a study?
No such study was located. Searches of PubMed and Europe PMC returned only anti-doping analytical methods in which both compounds appear as target analytes, and scoping reviews of image and performance enhancing drugs that describe them in separate sections. No published experiment administered both to the same subjects or ran them as parallel arms.
- Does stimulating the pituitary produce the same result as injecting growth hormone?
The published comparison closest to that question used the unmodified GHRH(1-29) fragment rather than CJC-1295. In 43 prepubertal children with growth hormone deficiency of hypothalamic origin randomised over six months, height velocity was comparable between the high-dose releasing-hormone group and the growth hormone group, but an increase in height standard deviation score for bone age occurred only in the growth hormone arm. A releasing-hormone analogue also depends on pituitary somatotroph reserve, which exogenous growth hormone does not.
- What endpoints did the published CJC-1295 studies in humans actually measure?
Endocrine surrogates only. The phase I and phase II work reported growth hormone and IGF-1 concentrations, the duration of their elevation, secretion pulsatility and serum protein profile changes. Single injections raised mean growth hormone roughly two- to tenfold for six or more days and IGF-I roughly 1.5- to threefold for nine to eleven days. No clinical outcome such as body composition, lean mass, recovery or function was assessed.
- Why does the form of CJC-1295 matter in this comparison?
Because essentially all human data pertain to the DAC-conjugated compound, which binds albumin covalently and has a plasma half-life of roughly one to two weeks. The non-DAC form, modified GRF(1-29), has a short duration comparable to sermorelin, and no peer-reviewed randomised controlled trial of it was identified. Statements about CJC-1295 drawn from the 2005 to 2009 studies do not automatically transfer to the non-DAC form.
- Which of the two has long-term safety data in people?
Only somatropin, and even there the picture is qualified. A prospective registry of 5040 children covering 19,878 patient-years reported adverse drug reactions in 7.0% of participants, serious reactions in 0.3% and a malignancy standardised incidence ratio of 1.1, while a meta-analysis of adult mortality concluded that selection and time bias precluded high-quality evidence that replacement improves mortality. For CJC-1295 no long-term human safety dataset exists in either form.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.